XML 22 R6.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Cash flows from operating activities:    
Net income (loss) $ (5,650,039) $ (3,602,799)
Discontinued operations net of tax 0 1,994,322
Net income (loss) from continuing operations (5,650,039) (5,597,121)
Adjustments to reconcile net income (loss) to net cash flows provided by (used in) operating activities:    
Depreciation and amortization expense 5,328,113 4,606,366
Deferred tax expense 0 0
Share-based compensation 447,503 741,867
Decrease in non-cash contingent consideration (2,088,296) (1,147,750)
Decrease (Increase) in cash surrender value of life insurance policies over premiums paid 613,657 (282,207)
Noncash interest expense 11,237 34,053
Noncash gain on RediTrex transaction (37,882) 0
Noncash investment gains (611,330) 0
Gain on forgiveness of debt 0 (2,187,140)
Net changes in assets and liabilities affecting operating activities:    
Accounts receivable (6,115,640) 5,500,367
Inventories 911,078 4,816,450
Prepaid, other current assets and other assets 689,260 (35,568)
Accounts payable and other current liabilities 14,536,076 (757,591)
Other long-term liabilities 419,659 (1,343,605)
Net cash provided by operating activities from continuing operations 8,453,396 4,348,121
Discontinued operations 0 1,994,322
Net cash provided by (used in) operating activities 8,453,396 6,342,443
Cash flows from investing activities:    
Additions to property and equipment (102,148) (103,532)
Additions to intangible assets (1,971,662) (250,930)
Return of RediTrex 1,000,000 0
Proceeds from surrender of life insurance policies 0 85,944
Premiums paid for life insurance policies 0 (33,375)
Life insurance policy proceeds received 877,597 0
Settlement of patent litigation 21,757 0
Cash paid for acquisition (13,500,000) 0
Note receivable investment funding 0 (200,000)
Net cash provided by (used in) investing activities (13,674,456) (501,893)
Cash flows from financing activities:    
Borrowings on line of credit 52,900,000 59,000,000
Repayments on line of credit (51,700,000) (59,000,000)
Repurchase of common shares (1,053,042) (1,386,849)
Cash settlement of contingent consideration (2,208,744) (2,166,681)
Net cash used in financing activities (2,061,786) (3,553,530)
Net increase (decrease) in cash and cash equivalents (7,282,846) 2,287,020
Cash and cash equivalents, beginning of year 27,040,816 24,753,796
Cash and cash equivalents, end of year 19,757,970 27,040,816
Net cash paid (refunded) during the year for:    
Interest 523,161 63,978
Income taxes 3,300 (327)
Noncash investing and financing activities:    
Change in unpaid invoices for purchases of intangibles (1,803,403) (43,471)
Change in unpaid invoices for offering costs (94,689) (90,512)
Recognition of operating lease assets and liabilities through adoption of ASC 842 4,590,978 0
RediTrex forgiveness of milestone payable (1,000,000) 0
Return of common stock - Methotrexate $ 399,600 $ 0